Equities Analysts Issue Forecasts for Femasys Inc.’s Q3 2024 Earnings (NASDAQ:FEMY)

Femasys Inc. (NASDAQ:FEMY) – Analysts at HC Wainwright reduced their Q3 2024 earnings per share (EPS) estimates for shares of Femasys in a report released on Thursday, September 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.20) for the quarter, down from their previous forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.20) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at ($0.02) EPS.

Femasys (NASDAQ:FEMY) last announced its earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.50 million. Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%.

Separately, Chardan Capital dropped their price target on Femasys from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Femasys Stock Performance

NASDAQ FEMY opened at $1.12 on Monday. The company has a market capitalization of $24.89 million, a P/E ratio of -1.33 and a beta of -2.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 6.47. Femasys has a 52-week low of $0.25 and a 52-week high of $4.75. The company has a fifty day moving average of $1.09 and a 200-day moving average of $1.28.

Hedge Funds Weigh In On Femasys

An institutional investor recently raised its position in Femasys stock. CM Management LLC raised its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 6.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the period. CM Management LLC owned about 1.91% of Femasys worth $484,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.